Brief: Initial Data From Allarity's Phase 2 Trial Of IXEMPRA Indicate Potential For Improved Clinical Benefit In DRP-Selected Metastatic Breast Cancer Patients
05/07/2023 14:53
July 5 (Reuters) - Allarity Therapeutics Inc ALLR.O :
* INITIAL DATA FROM ALLARITY’S PHASE 2 TRIAL OF IXEMPRA®
INDICATE
POTENTIAL FOR IMPROVED CLINICAL BENEFIT IN DRP®-SELECTED
METASTATIC BREAST CANCER PATIENTS
* INITIAL DATA FROM ALLARITY’S PHASE 2 TRIAL OF IXEMPRA®
INDICATE
POTENTIAL FOR IMPROVED CLINICAL BENEFIT IN DRP®-SELECTED
METASTATIC BREAST CANCER PATIENTS
* ALLARITY THERAPEUTICS INC - ANTICIPATES AN ADDITIONAL
INTERIM
DATA READOUT BEFORE END OF THIS YEAR
Source text for Eikon: ID:nGNX43wfLk
Further company coverage: ALLR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic